Carbamylated LDL

Advances in Clinical Chemistry

Volumn 51, Issue C, 2010, Pages 25-52

  Basnakian, Alexei G ^a,b   Shah, Sudhir V ^a,b   Ok, Ercan ^c   Altunel, Ekrem ^c   Apostolov, Eugene O ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^c EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Atherosclerosis; Carbamylated low density lipoprotein; Chronic kidney failure; Urea; Uremia

Indexed keywords

AUTOANTIBODY; CARBAMYL LDL; CARBAMYL-LDL; LOW DENSITY LIPOPROTEIN; PLASMA PROTEIN;

ANIMAL; ATHEROSCLEROSIS; BLOOD; BOOK; CELL ADHESION; CELL CULTURE; CELL PROLIFERATION; ENDOTHELIUM CELL; HUMAN; IMMUNOLOGY; METABOLISM; MONOCYTE; PHYSIOLOGY; UREMIA; COMPLICATION;

ANIMALS; ATHEROSCLEROSIS; AUTOANTIBODIES; BLOOD PROTEINS; CELL ADHESION; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; LIPOPROTEINS, LDL; MONOCYTES; UREMIA;

EID: 77955900040     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(10)51002-3     Document Type: Book

References (185)

1. National Center for Health Statistics Health United States, 2008 With Chartbook, in Bethesda, MD, NIH, National Institute of Diabetes and Digestive and Kidney Diseases 2009, U.S. Government Printing Office, Hyattsville, MD.
2. Yao Q., Pecoits-Filho R., Lindholm B., Stenvinkel P. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand. J. Urol. Nephrol. 2004, 38:405.
3. Dessein P.H., Joffe B.I., Veller M.G., Stevens B.A., Tobias M., Reddi K., et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J. Rheumatol. 2005, 32:435.
4. Colombo B.M., Cacciapaglia F., Puntoni M., Murdaca G., Rossi E., Rodriguez G., et al. Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). Autoimmun. Rev. 2009, 8:309.
5. Chambless L.E., Folsom A.R., Davis V., Sharrett R., Heiss G., Sorlie P., et al. Risk factors for progression of common carotid atherosclerosis: the Atherosclerosis Risk in Communities Study, 1987-1998. Am. J. Epidemiol. 2002, 155:38.
6. Beckman J.A., Creager M.A., Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002, 287:2570.
7. Mantov S., Mircheva T., Todorova K., Dineva R. Influence of diabetes and arterial hypertension on the immune mechanism of atherosclerosis. Atherosclerosis 1999, 144:158.
8. Jensen J.S. Microalbuminaria and the risk of atherosclerosis. Clinical epidemiological and physiological investigations. Dan. Med. Bull. 2000, 47:63.
9. Chade A.R., Lerman A., Lerman L.O. Kidney in early atherosclerosis. Hypertension 2005, 45:1042.
10. Lin C.Y., Lin L.Y., Kuo H.K., Lin J.W. Chronic kidney disease, atherosclerosis, and cognitive and physical function in the geriatric group of the National Health and Nutrition Survey 1999-2002. Atherosclerosis 2009, 202:312.
11. Levey A.S., Coresh J., Balk E., Kausz A., Levin A., Steffes M.W., et al. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Ann. Intern. Med. 2003, 139:137.
12. Nissenson A.R., Pereira B.J., Collins A.J., Steinberg E.P. Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization. Am. J. Kidney Dis. 2001, 37:1177.
13. Chadban S.J., Briganti E.M., Kerr P.G., Dunstan D.W., Welborn T.A., Zimmet P.Z., et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J. Am. Soc. Nephrol. 2003, 14:S131.
14. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J., Culleton B., Hamm L.L., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108:2154.
15. Kumar J., Shah S.V. Kidney disease as an independent risk factor for cardiovascular events. J. Ren. Nutr. 2005, 15:99.
16. Schiffrin E.L., Lipman M.L., Mann J.F. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007, 116:85.
17. Reikes S.T. Trends in end-stage renal disease. Epidemiology, morbidity, and mortality. Postgrad. Med. 2000, 108:124.
18. Venkatesan J., Henrich W.L. Anemia, hypertension, and myocardial dysfunction in end-stage renal disease. Semin. Nephrol. 1997, 17:257.
19. London G.M. Alterations of arterial function in end-stage renal disease. Nephron 2000, 84:111.
20. London G.M. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin. Dial. 2003, 16:85.
21. London G.M. Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J. Am. Soc. Nephrol. 2003, 14:S305.
22. Menon V., Gul A., Sarnak M.J. Cardiovascular risk factors in chronic kidney disease. Kidney Int. 2005, 68:1413.
23. Selhub J. Homocysteine metabolism. Annu. Rev. Nutr. 1999, 19:217.
24. Mayer E.L., Jacobsen D.W., Robinson K. Homocysteine and coronary atherosclerosis. J. Am. Coll. Cardiol. 1996, 27:517.
25. McCully K.S. Homocystine, atherosclerosis and thrombosis: implications for oral contraceptive users. Am. J. Clin. Nutr. 1975, 28:542.
26. Siri P.W., Verhoef P., Kok F.J. Vitamins B6, B12, and folate: association with plasma total homocysteine and risk of coronary atherosclerosis. J. Am. Coll. Nutr. 1998, 17:435.
27. Hofmann M.A., Lalla E., Lu Y., Gleason M.R., Wolf B.M., Tanji N., et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J. Clin. Invest. 2001, 107:675.
28. Zhou J., Moller J., Danielsen C.C., Bentzon J., Ravn H.B., Austin R.C., et al. Dietary supplementation with methionine and homocysteine promotes early atherosclerosis but not plaque rupture in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1470.
29. Zoungas S., McGrath B.P., Branley P., Kerr P.G., Muske C., Wolfe R., et al. Cardiovascular morbidity and mortality in the atherosclerosis and folic acid supplementation trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J. Am. Coll. Cardiol. 2006, 47:1108.
30. Mann J.F., Sheridan P., McQueen M.J., Held C., Arnold J.M., Fodor G., et al. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease-results of the renal Hope-2 study. Nephrol. Dial. Transplant. 2008, 23:645.
31. Bonaa K.H., Njolstad I., Ueland P.M., Schirmer H., Tverdal A., Steigen T., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N. Engl. J. Med. 2006, 354:1578.
32. Toole J.F., Malinow M.R., Chambless L.E., Spence J.D., Pettigrew L.C., Howard V.J., et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004, 291:565.
33. Zalba G., Fortuno A., Diez J. Oxidative stress and atherosclerosis in early chronic kidney disease. Nephrol. Dial. Transplant. 2006, 21:2686.
34. Himmelfarb J., Stenvinkel P., Ikizler T.A., Hakim R.M. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002, 62:1524.
35. Danielski M., Ikizler T.A., McMonagle E., Kane J.C., Pupim L., Morrow J., et al. Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. Am. J. Kidney Dis. 2003, 42:286.
36. Morena M., Delbosc S., Dupuy A.M., Canaud B., Cristol J.P. Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysis-associated inflammation. Hemodial. Int. 2005, 9:37.
37. Annuk M., Zilmer M., Lind L., Linde T., Fellstrom B. Oxidative stress and endothelial function in chronic renal failure. J. Am. Soc. Nephrol. 2001, 12:2747.
38. Vaziri N.D. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin. Nephrol. 2004, 24:469.
39. Himmelfarb J., Hakim R.M. Oxidative stress in uremia. Curr. Opin. Nephrol. Hypertens. 2003, 12:593.
40. Lahera V., Goicoechea M., de Vinuesa S.G., Oubina P., Cachofeiro V., Gomez-Campdera F., et al. Oxidative stress in uremia: the role of anemia correction. J. Am. Soc. Nephrol. 2006, 17:S174.
41. Muller C., Eisenbrand G., Gradinger M., Rath T., Albert F.W., Vienken J., et al. Effects of hemodialysis, dialyser type and iron infusion on oxidative stress in uremic patients. Free Radic. Res. 2004, 38:1093.
42. Zoccali C., Mallamaci F., Asahia K., Benedetto F.A., Tripepi G., Tripepi R., et al. Pentosidine, carotid atherosclerosis and alterations in left ventricular geometry in hemodialysis patients. J. Nephrol. 2001, 14:293.
43. Fujisawa M., Haramaki R., Miyazaki H., Imaizumi T., Okuda S. Role of lipoprotein (a) and TGF-beta 1 in atherosclerosis of hemodialysis patients. J. Am. Soc. Nephrol. 2000, 11:1889.
44. Ishimura E., Shoji T., Emoto M., Motoyama K., Shinohara K., Matsumoto N., et al. Renal insufficiency accelerates atherosclerosis in patients with type 2 diabetes mellitus. Am. J. Kidney Dis. 2001, 38:S186.
45. Kimak E., Solski J., Janicka L., Zagojska M. Lipid and lipoprotein ratios as risk factors of atherosclerosis in patients with chronic renal insufficiency (CRI). Int. Urol. Nephrol. 1999, 31:263.
46. Shoji T., Emoto M., Tabata T., Kimoto E., Shinohara K., Maekawa K., et al. Advanced atherosclerosis in predialysis patients with chronic renal failure. Kidney Int. 2002, 61:2187.
47. Hojs R., Hojs-Fabjan T., Balon B.P. Atherosclerosis in patients with end-stage renal failure prior to initiation of hemodialysis. Ren. Fail. 2003, 25:247.
48. Buzello M., Tornig J., Faulhaber J., Ehmke H., Ritz E., Amann K. The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia. J. Am. Soc. Nephrol. 2003, 14:311.
49. Bro S., Moeller F., Andersen C.B., Olgaard K., Nielsen L.B. Increased expression of adhesion molecules in uremic atherosclerosis in apolipoprotein-E-deficient mice. J. Am. Soc. Nephrol. 2004, 15:1495.
50. Elitok S., Brodsky S.V., Patschan D., Orlova T., Lerea K.M., Chander P., et al. Cyclic arginine-glycine-aspartic acid peptide inhibits macrophage infiltration of the kidney and carotid artery lesions in apo-E-deficient mice. Am. J. Physiol. Ren. Physiol. 2006, 290:F159.
51. Ivanovski O., Szumilak D., Nguyen-Khoa T., Ruellan N., Phan O., Lacour B., et al. The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int. 2005, 67:2288.
52. Massy Z.A., Ivanovski O., Nguyen-Khoa T., Angulo J., Szumilak D., Mothu N., et al. Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J. Am. Soc. Nephrol. 2005, 16:109.
53. Phan O., Ivanovski O., Nguyen-Khoa T., Mothu N., Angulo J., Westenfeld R., et al. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 2005, 112:2875.
54. Stephens N.G., Parsons A., Schofield P.M., Kelly F., Cheeseman K., Mitchinson M.J. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996, 347:781.
55. Boaz M., Smetana S., Weinstein T., Matas Z., Gafter U., Iaina A., et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000, 356:1213.
56. Tepel M., van der Giet M., Statz M., Jankowski J., Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003, 107:992.
57. Kris-Etherton P.M., Lichtenstein A.H., Howard B.V., Steinberg D., Witztum J.L. Antioxidant vitamin supplements and cardiovascular disease. Circulation 2004, 110:637.
58. Mann J.F.E., Lonn E.M., Yi Q., Gerstein H.C., Hoogwerf B.J., Pogue J., et al. Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE Study. Kidney Int. 2004, 65:1375.
59. GISSI-Prevenzione Investigators Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999, 354:447.
60. Yusuf S., Dagenais G., Pogue J., Bosch J., Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000, 342:154.
61. Lonn E. Do antioxidant vitamins protect against atherosclerosis? The proof is still lacking. J. Am. Coll. Cardiol. 2001, 38:1795.
62. Tardif J.C., Gregoire J., L'Allier P.L., Ibrahim R., Anderson T.J., Reeves F., et al. Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. Atherosclerosis 2008, 197:480.
63. Schuh J., Fairclough G.F., Haschemeyer R.H. Oxygen-mediated heterogeneity of apo-low-density lipoprotein. Proc. Natl. Acad. Sci. USA 1978, 75:3173.
64. Sawamura T., Kume N., Aoyama T., Moriwaki H., Hoshikawa H., Aiba Y., et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997, 386:73.
65. Basu S.K., Goldstein J.L., Anderson G.W., Brown M.S. Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. Proc. Natl. Acad. Sci. USA 1976, 73:3178.
66. Goldstein J.L., Ho Y.K., Basu S.K., Brown M.S. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. USA 1979, 76:333.
67. Steinbrecher U.P., Fisher M., Witztum J.L., Curtiss L.K. Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine. J. Lipid Res. 1984, 25:1109.
68. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab. Res. Rev. 2001, 17:436.
69. Wang X., Bucala R., Milne R. Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products. Proc. Natl. Acad. Sci. USA 1998, 95:7643.
70. Dimmeler S., Hermann C., Zeiher A.M. Apoptosis of endothelial cells. Contribution to the pathophysiology of atherosclerosis?. Eur. Cytokine Netw. 1998, 9:697.
71. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340:115.
72. Han J., Hajjar D.P., Febbraio M., Nicholson A.C. Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36. J. Biol. Chem. 1997, 272:21654.
73. Kita T., Kume N., Ishii K., Horiuchi H., Arai H., Yokode M., et al. Oxidized LDL and expression of monocyte adhesion molecules. Diab. Res. Clin. Pract. 1999, 45:123.
74. Kamanna V.S., Pai R., Ha H., Kirschenbaum M.A., Roh D.D. Oxidized low-density lipoprotein stimulates monocyte adhesion to glomerular endothelial cells. Kidney Int. 1999, 55:2192.
75. Zhao S.P., Xu D.Y. Oxidized lipoprotein(a) enhanced the expression of P-selectin in cultured human umbilical vein endothelial cells. Thromb. Res. 2000, 100:501.
76. Rong R., Ramachandran S., Santanam N., Murphy A.A., Parthasarathy S. Induction of monocyte chemotactic protein-1 in peritoneal mesothelial and endometrial cells by oxidized low-density lipoprotein and peritoneal fluid from women with endometriosis. Fertil. Steril. 2002, 78:843.
77. Dwivedi A., Anggard E.E., Carrier M.J. Oxidized LDL-mediated monocyte adhesion to endothelial cells does not involve NFkappaB. Biochem. Biophys. Res. Commun. 2001, 284:239.
78. Choy J.C., Granville D.J., Hunt D.W., McManus B.M. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J. Mol. Cell. Cardiol. 2001, 33:1673.
79. Galle J., Schneider R., Heinloth A., Wanner C., Galle P.R., Conzelmann E., et al. Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: role of oxidative stress. Kidney Int. 1999, 55:1450.
80. Mallat Z., Tedgui A. Apoptosis in the vasculature: mechanisms and functional importance. Br. J. Pharmacol. 2000, 130:947.
81. Dart A.M., Chin-Dusting J.P. Lipids and the endothelium. Cardiovasc. Res. 1999, 43:308.
82. Galle J., Heermeier K., Wanner C. Atherogenic lipoproteins, oxidative stress, and cell death. Kidney Int. Suppl. 1999, 71:S62.
83. Galle J., Heinloth A., Wanner C., Heermeier K. Dual effect of oxidized LDL on cell cycle in human endothelial cells through oxidative stress. Kidney Int. Suppl. 2001, 78:S120.
84. Napoli C., Quehenberger O., De Nigris F., Abete P., Glass C.K., Palinski W. Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells. FASEB J. 2000, 14:1996.
85. Steinbrecher U.P., Witztum J.L., Parthasarathy S., Steinberg D. Decrease in reactive amino groups during oxidation or endothelial cell modification of LDL. Correlation with changes in receptor-mediated catabolism. Arteriosclerosis 1987, 7:135.
86. Li D., Mehta J.L. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler. Thromb. Vasc. Biol. 2000, 20:1116.
87. Hirano K., Yamashita S., Nakagawa Y., Ohya T., Matsuura F., Tsukamoto K., et al. Expression of human scavenger receptor class B type I in cultured human monocyte-derived macrophages and atherosclerotic lesions. Circ. Res. 1999, 85:108.
88. Gu L., Okada Y., Clinton S.K., Gerard C., Sukhova G.K., Libby P., et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell 1998, 2:275.
89. Van Tits L., De Graaf J., Hak-Lemmers H., Bredie S., Demacker P., Holvoet P., et al. Increased levels of low-density lipoprotein oxidation in patients with familial hypercholesterolemia and in end-stage renal disease patients on hemodialysis. Lab. Invest. 2003, 83:13.
90. Takenaka T., Takahashi K., Kobayashi T., Oshima E., Iwasaki S., Suzuki H. Oxidized low density lipoprotein (Ox-LDL) as a marker of atherosclerosis in hemodialysis (HD) patients. Clin. Nephrol. 2002, 58:33.
91. Futatsuyama M., Oiwa T., Komatsu Y. Correlation between oxidized low-density lipoprotein and other factors in patients on peritoneal dialysis. Adv. Perit. Dial. 2002, 18:192.
92. Tertov V.V., Kaplun V.V., Orekhov A.N. Lack of correlation between degree of human plasma low density lipoprotein oxidation and its atherogenic potential. Biofactors 1997, 6:139.
93. Napoli C., Witztum J.L., Calara F., de Nigris F., Palinski W. Maternal hypercholesterolemia enhances atherogenesis in normocholesterolemic rabbits, which is inhibited by antioxidant or lipid-lowering intervention during pregnancy: an experimental model of atherogenic mechanisms in human fetuses. Circ. Res. 2000, 87:946.
94. Collins A.R., Lyon C.J., Xia X., Liu J.Z., Tangirala R.K., Yin F., et al. Age-accelerated atherosclerosis correlates with failure to upregulate antioxidant genes. Circ. Res. 2009, 104:e42.
95. Lyons T.J., Jenkins A.J. Lipoprotein glycation and its metabolic consequences. Curr. Opin. Lipidol. 1997, 8:174.
96. Shen G.X. Impact and mechanism for oxidized and glycated lipoproteins on generation of fibrinolytic regulators from vascular endothelial cells. Mol. Cell. Biochem. 2003, 246:69.
97. Kraus L.M., Kraus A.P. The search for the uremic toxin: the case for carbamoylation of amino acids and proteins. Wien. Klin. Wochenschr. 1998, 110:521.
98. Bailey J.L., Mitch W.E. The search for the uremic toxin: the case for metabolic acidosis. Wien. Klin. Wochenschr. 1997, 109:7.
99. Nilsson L., Lundquist P., Kagedal B., Larsson R. Plasma cyanate concentrations in chronic renal failure. Clin. Chem. 1996, 42:482.
100. Kraus L.M., Kraus A.P. Carbamoylation of amino acids and proteins in uremia. Kidney Int. Suppl. 2001, 78:S102.
101. Oram J.D., Reiter B. The inhibition of streptococci by lactoperoxidase, thiocyanate and hydrogen peroxide. The oxidation of thiocyanate and the nature of the inhibitory compound. Biochem. J. 1966, 100:382.
102. Wilson I.R., Harris G.M. Oxidation of thiocyanate ion by hydrogen peroxide. J. Am. Chem. Soc. 1960, 82:4515.
103. Arlandson M., Decker T., Roongta V.A., Bonilla L., Mayo K.H., MacPherson J.C., et al. Eosinophil peroxidase oxidation of thiocyanate. Characterization of major reaction products and a potential sulfhydryl-targeted cytotoxicity system. J. Biol. Chem. 2001, 276:215.
104. Wang Z., Nicholls S.J., Rodriguez E.R., Kummu O., Horkko S., Barnard J., et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat. Med. 2007, 13:1176.
105. Chung J., Wood J.L. Oxidation of thiocyanate to cyanide catalyzed by hemoglobin. J. Biol. Chem. 1971, 246:555.
106. Schulz V. Clinical pharmacokinetics of nitroprusside, cyanide, thiosulphate and thiocyanate. Clin. Pharmacokinet. 1984, 9:239.
107. Weisgraber K.H., Innerarity T.L., Mahley R.W. Role of lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts. J. Biol. Chem. 1978, 253:9053.
108. Park K.D., Mun K.C., Chang E.J., Park S.B., Kim H.C. Inhibition of erythropoietin activity by cyanate. Scand. J. Urol. Nephrol. 2004, 38:69.
109. Lapko V.N., Smith D.L., Smith J.B. Methylation and carbamylation of human gamma-crystallins. Protein Sci. 2003, 12:1762.
110. Pieniazek A., Gwozdzinski K. Carbamylation of proteins leads to alterations in the membrane structure of erythrocytes. Cell. Mol. Biol. Lett. 2003, 8:127.
111. Kraus L.M., Gaber L., Handorf C.R., Marti H.P., Kraus A.P. Carbamoylation of glomerular and tubular proteins in patients with kidney failure: a potential mechanism of ongoing renal damage. Swiss Med. Wkly 2001, 131:139.
112. Ganea E., Harding J.J. Inhibition of 6-phosphogluconate dehydrogenase by carbamylation and protection by alpha-crystallin, a chaperone-like protein. Biochem. Biophys. Res. Commun. 1996, 222:626.
113. Wynckel A., Randoux C., Millart H., Desroches C., Gillery P., Canivet E., et al. Kinetics of carbamylated haemoglobin in acute renal failure. Nephrol. Dial. Transplant. 2000, 15:1183.
114. Kairaitis L.K., Yuill E., Harris D.C. Determinants of haemoglobin carbamylation in haemodialysis and peritoneal dialysis patients. Nephrol. Dial. Transplant. 2000, 15:1431.
115. Fluckiger R., Harmon W., Meier W., Loo S., Gabbay K.H. Hemoglobin carbamylation in uremia. N. Engl. J. Med. 1981, 304:823.
116. Chachou A., Randoux C., Millart H., Chanard J., Gillery P. Influence of in vivo hemoglobin carbamylation on HbA1c measurements by various methods. Clin. Chem. Lab. Med. 2000, 38:321.
117. Davenport A., Jones S., Goel S., Astley J.P., Feest T.G. Carbamylated hemoglobin: a potential marker for the adequacy of hemodialysis therapy in end-stage renal failure. Kidney Int. 1996, 50:1344.
118. Hasuike Y., Nakanishi T., Maeda K., Tanaka T., Inoue T., Takamitsu Y. Carbamylated hemoglobin as a therapeutic marker in hemodialysis. Nephron 2002, 91:228.
119. Hood W., de la Morena E., Grisolia S. Increased susceptibility of carbamylated glutamate dehydrogenase to proteolysis. Acta Biol. Med. Ger. 1977, 36:1667.
120. Kuckel C.L., Lubit B.W., Lambooy P.K., Farnsworth P.N. Methylisocyanate and actin polymerization: the in vitro effects of carbamylation. Biochim. Biophys. Acta 1993, 1162:143.
121. Trepanier D.J., Thibert R.J., Draisey T.F., Caines P.S. Carbamylation of erythrocyte membrane proteins: an in vitro and in vivo study. Clin. Biochem. 1996, 29:347.
122. Apostolov E.O., Shah S.V., Ok E., Basnakian A.G. Quantification of carbamylated LDL in human sera by a new sandwich ELISA. Clin. Chem. 2005, 51:719.
123. Jeppsson J.O., Jerntorp P., Sundkvist G., Englund H., Nylund V. Measurement of hemoglobin A1c by a new liquid-chromatographic assay: methodology, clinical utility, and relation to glucose tolerance evaluated. Clin. Chem. 1986, 32:1867.
124. Kwan J.T., Carr E.C., Bending M.R., Barron J.L. Determination of carbamylated hemoglobin by high-performance liquid chromatography. Clin. Chem. 1990, 36:607.
125. Balion C.M., Draisey T.F., Thibert R.J. Carbamylated hemoglobin and carbamylated plasma protein in hemodialyzed patients. Kidney Int. 1998, 53:488.
126. Kee P., Bais R., Sobecki S.K., Branford S., Rye K.A., Barter P.J. Indirect sandwich enzyme-linked immunosorbent assay (ELISA) for plasma apolipoprotein E. Ann. Clin. Biochem. 1996, 33(Pt 2):119.
127. Chang C.K., Tso T.K., Snook J.T., Zipf W.B., Lozano R.A. Sandwich enzyme-linked immunosorbent assay for plasma cholesteryl ester transfer protein concentration. Clin. Biochem. 1999, 32:257.
128. Cao Y., Smith W.C., Bowsher R.R. A sensitive chemiluminescent enzyme immunoassay for the bioanalysis of carboxyl-terminal B-chain analogues of human insulin. J. Pharm. Biomed. Anal. 2001, 26:53.
129. Canal J., Girard M.L. Properties of heavy (Sf 4-6) carbamylated human betalipoproteins. Ann. Biol. Clin. Paris 1973, 31:97.
130. Gonen B., Goldberg A.P., Harter H.R., Schonfeld G. Abnormal cell-interactive properties of low-density lipoproteins isolated from patients with chronic renal failure. Metabolism 1985, 34:10.
131. Horkko S., Savolainen M.J., Kervinen K., Kesaniemi Y.A. Carbamylation-induced alterations in low-density lipoprotein metabolism. Kidney Int. 1992, 41:1175.
132. Horkko S., Huttunen K., Kervinen K., Kesaniemi Y.A. Decreased clearance of uraemic and mildly carbamylated low-density lipoprotein. Eur. J. Clin. Invest. 1994, 24:105.
133. Kronenberg F., Ikewaki K., Schaefer J.R., Konig P., Dieplinger H. Kinetic studies of atherogenic lipoproteins in hemodialysis patients: do they tell us more about their pathology?. Semin. Dial. 2007, 20:554.
134. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868.
135. Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol. 2003, 23:168.
136. Ok E., Basnakian A.G., Apostolov E.O., Barri Y.M., Shah S.V. Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease. Kidney Int. 2005, 68:173.
137. Apostolov E.O., Basnakian A.G., Yin X., Ok E., Shah S.V. Modified LDLs induce proliferation-mediated death of human vascular endothelial cells through MAPK pathway. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H1836.
138. Apostolov E.O., Shah S.V., Ok E., Basnakian A.G. Carbamylated low-density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. Arterioscler. Thromb. Vasc. Biol. 2007, 27:826.
139. Gonen B., Cole T., Hahm K.S. The interaction of carbamylated low-density lipoprotein with cultured cells. Studies with human fibroblasts, rat peritoneal macrophages and human monocyte-derived macrophages. Biochim. Biophys. Acta 1983, 754:201.
140. Boullier A., Bird D.A., Chang M.K., Dennis E.A., Friedman P., Gillotre-Taylor K., et al. Scavenger receptors, oxidized LDL, and atherosclerosis. Ann. NY Acad. Sci. 2001, 947:214.
141. Kesaniemi Y.A., Witztum J.L., Steinbrecher U.P. Receptor-mediated catabolism of low density lipoprotein in man. Quantitation using glucosylated low density lipoprotein. J. Clin. Invest. 1983, 71:950.
142. Krieger M., Herz J. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu. Rev. Biochem. 1994, 63:601.
143. Wehr H., Mirkiewicz E., Rodo M., Bednarska-Makaruk M. Uptake of acetaldehyde-modified (ethylated) low-density lipoproteins by mouse peritoneal macrophages. Alcohol 2002, 26:163.
144. Horiuchi S., Sakamoto Y., Sakai M. Scavenger receptors for oxidized and glycated proteins. Amino Acids 2003, 25:283.
145. Mimeault M., Moore E., Moniaux N., Henichart J.P., Depreux P., Lin M.F., et al. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells. Int. J. Cancer 2006, 118:1022.
146. Greaves D.R., Gordon S. Thematic review series: the immune system and atherogenesis. Recent insights into the biology of macrophage scavenger receptors. J. Lipid Res. 2005, 46:11.
147. Apostolov E.O., Shah S.V., Ray D., Basnakian A.G. Scavenger receptors of endothelial cells mediate the uptake and cellular proatherogenic effects of carbamylated LDL. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1622.
148. Stewart B.W., Nagarajan S. Recombinant CD36 inhibits oxLDL-induced ICAM-1-dependent monocyte adhesion. Mol. Immunol. 2006, 43:255.
149. Li D., Mehta J.L. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 2000, 101:2889.
150. Thorne S.A., Abbot S.E., Stevens C.R., Winyard P.G., Mills P.G., Blake D.R. Modified low density lipoprotein and cytokines mediate monocyte adhesion to smooth muscle cells. Atherosclerosis 1996, 127:167.
151. Asci G., Basci A., Shah S.V., Basnakian A., Toz H., Ozkahya M., et al. Carbamylated low-density lipoprotein induces proliferation and increases adhesion molecule expression of human coronary artery smooth muscle cells. Nephrology (Carlton) 2008.
152. Apostolov E.O., Shah S.V., Basnakian A.G. LDL carbamylation in accelerated atherosclerosis caused by chronic renal failure in mice. Proceedings of the 31st ASN Annual Meeting, Philadelphia, PA, Nov 2-7 2008, 384A.
153. Itabe H., Yamamoto H., Imanaka T., Shimamura K., Uchiyama H., Kimura J., et al. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J. Lipid Res. 1996, 37:45.
154. Apostolov E.O., Shah S.V., Ok E., Basnakian A.G. Quantification of carbamylated LDL in human sera by a new sandwich ELISA. Clin. Chem. 2005, 51:719.
155. Dimitri G. Manual ELISA assays on tPA and PAI-1 automated on Novapath I.S. preliminary report. Boll. Chim. Farm. 1993, 132:272.
156. Clerico A., Del Chicca M.G., Zucchelli G.C., Salutini L., Mercuri A., Scarlattini M. Performance of a fully automated fluorometric enzyme immunoassay for serum myoglobin measurement. J. Nucl. Biol. Med. 1993, 37:83.
157. Ok E., Basnakian A.G., Apostolov E.O., Barri Y.M., Shah S.V. Elevation of both carbamylated LDL and autoantibody to carbamylated LDL in dialysis patients. J. Am. Soc. Nephrol. 2002, 13:219A.
158. Kawamoto S., Shi Q., Nitta Y., Miyazaki J., Allen M.D. Widespread and early myocardial gene expression by adeno-associated virus vector type 6 with a beta-actin hybrid promoter. Mol. Ther. 2005, 11:980.
159. Nishizawa Y., Shoji T., Maekawa K., Nagasue K., Okuno S., Kim M., et al. Intima-media thickness of carotid artery predicts cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis. 2003, 41:S76.
160. Kotani K., Maekawa M., Kanno T., Kondo A., Toda N., Manabe M. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim. Biophys. Acta 1994, 1215:121.
161. Holvoet P., Perez G., Zhao Z., Brouwers E., Bernar H., Collen D. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J. Clin. Invest. 1995, 95:2611.
162. Kohno H., Sueshige N., Oguri K., Izumidate H., Masunari T., Kawamura M., et al. Simple and practical sandwich-type enzyme immunoassay for human oxidatively modified low density lipoprotein using antioxidized phosphatidylcholine monoclonal antibody and antihuman apolipoprotein-B antibody. Clin. Biochem. 2000, 33:243.
163. Bosmans J.L., Holvoet P., Dauwe S.E., Ysebaert D.K., Chapelle T., Jurgens A., et al. Oxidative modification of low-density lipoproteins and the outcome of renal allografts at 1 1/2years. Kidney Int. 2001, 59:2346.
164. Ok E., Basnakian A.G., Barri Y.M., Shah S.V. Carbamylated LDL induces injury to human endothelial cells. J. Am. Soc. Nephrol. 2001, 12:516A.
165. Ok E., Basnakian A.G., Shah S.V. Increased expression of adhesion molecules induced by carbamylated LDL. J. Am. Soc. Nephrol. 2002, 13:340A.
166. Kraus L.M., Miyamura S., Pecha B.R., Kraus A.P. Carbamoylation of hemoglobin in uremic patients determined by antibody specific for homocitrulline (carbamoylated epsilon-N-lysine). Mol. Immunol. 1991, 28:459.
167. Wehr H., Milewski B., Pozniak M., Rodo M. Anti-low-density lipoprotein antibodies in alcoholics without and with liver disease and in social drinkers. Alcohol Alcohol. 1997, 32:43.
168. van Leeuwen M., Damoiseaux J., Duijvestijn A., Heeringa P., Gijbels M., de Winther M., et al. The IgM response to modified LDL in experimental atherosclerosis: hypochlorite-modified LDL IgM antibodies versus classical natural T15 IgM antibodies. Ann. NY Acad. Sci. 2009, 1173:274.
169. Vaarala O. Autoantibodies to modified LDLs and other phospholipid-protein complexes as markers of cardiovascular diseases. J. Intern. Med. 2000, 247:381.
170. Lopes-Virella M.F., Virella G. Clinical significance of the humoral immune response to modified LDL. Clin. Immunol. 2009.
171. Korpinen E., Groop P.H., Akerblom H.K., Vaarala O. Immune response to glycated and oxidized LDL in IDDM patients with and without renal disease. Diabet. Care 1997, 20:1168.
172. Sobal G., Menzel J., Sinzinger H. Why is glycated LDL more sensitive to oxidation than native LDL? A comparative study. Prostaglandins Leukot. Essent. Fatty Acids 2000, 63:177.
173. Song W., Barth J.L., Yu Y., Lu K., Dashti A., Huang Y., et al. Effects of oxidized and glycated LDL on gene expression in human retinal capillary pericytes. Invest. Ophthalmol. Vis. Sci. 2005, 46:2974.
174. Dong Y., Wu Y., Wu M., Wang S., Zhang J., Xie Z., et al. Activation of protease calpain by oxidized and glycated LDL increases the degradation of endothelial nitric oxide synthase. J. Cell. Mol. Med. 2009, 13:2899.
175. Diffley J.M., Wu M., Sohn M., Song W., Hammad S.M., Lyons T.J. Apoptosis induction by oxidized glycated LDL in human retinal capillary pericytes is independent of activation of MAPK signaling pathways. Mol. Vis. 2009, 15:135.
176. Barth J.L., Yu Y., Song W., Lu K., Dashti A., Huang Y., et al. Oxidised, glycated LDL selectively influences tissue inhibitor of metalloproteinase-3 gene expression and protein production in human retinal capillary pericytes. Diabetologia 2007, 50:2200.
177. Roxborough H.E., Young I.S. Carbamylation of proteins and atherogenesis in renal failure. Med. Hypotheses 1995, 45:125.
178. Crompton M., Rixon K.C., Harding J.J. Aspirin prevents carbamylation of soluble lens proteins and prevents cyanate-induced phase separation opacities in vitro: a possible mechanism by which aspirin could prevent cataract. Exp. Eye Res. 1985, 40:297.
179. Roberts K.A., Harding J.J. Ibuprofen, a putative anti-cataract drug, protects the lens against cyanate and galactose. Exp. Eye Res. 1990, 50:157.
180. Lewis B.S., Rixon K.C., Harding J.J. Bendazac prevents cyanate binding to soluble lens proteins and cyanate-induced phase-separation opacities in vitro: a possible mechanism by which bendazac could delay cataract. Exp. Eye Res. 1986, 43:973.
181. Yano M., Matsumura T., Senokuchi T., Ishii N., Murata Y., Taketa K., et al. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ. Res. 2007, 100:1442.
182. Mehta J.L., Hu B., Chen J., Li D. Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation. Arterioscler. Thromb. Vasc. Biol. 2003, 23:2203.
183. Berkels R., Hass U., Klaus W. The calcium antagonist nifedipine inhibits the uptake of acetylated LDL into endothelial cells. Naunyn Schmiedebergs Arch. Pharmacol. 2000, 362:91.
184. Schwedler S.B., Hansen-Hagge T., Reichert M., Schmiedeke D., Schneider R., Galle J., et al. Monomeric C-reactive protein decreases acetylated LDL uptake in human endothelial cells. Clin. Chem. 2009, 55:1728.
185. Napolitano M., De Pascale C., Wheeler-Jones C., Botham K.M., Bravo E. Effects of lycopene on the induction of foam cell formation by modified LDL. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E1820.